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Summary.-The urinary excretion patterns of oestrogen metabolites, including
unusual metabolites, were determined by gas chromatography and mass spectro-
metry for 63 women with advanced breast cancer and 39 normal postmenopausal
women. The concentration of total unusual metabolites excreted was found to be an
excellent discriminant between breast-cancer patients and controls (P<0.0001).
Discrimination between responders and non-responders to endocrine therapy was
attempted, using several different indices. Of these, the ratio of Classical Oestrogens
to Unusual Metabolites (CE/UM) proved a fair discriminant, but the product of this
ratio and the oestriol ratio (CE/UM x E3R) was much the best discriminant. This
product, termed a Pattern Index, has considerable potential, not only as a discrimin-
ant for selecting therapy, but also as a rapid index of patient response to that therapy.
IT IS NOW WELL ESTABLISHED that the
presence of functional oestrogen receptor
in a biopsy sample ofhuman breast cancer
reflects both a good chance of response to
endocrine therapy (Barnes et al., 1979;
Edwards et al., 1979; Hawkins et al., 1980;
Leake et al., ] 981a) and a better prognosis
(Knight et al., 1977; Bishop et al., 1979;
Hawkins et al., 1980; Leake et al., 1981b).
Before the advent of receptor analyses,
several steroid metabolic discriminants
were used, with varying degrees of success
(Bulbrook et al., 1960; 1971; Lemon et al.,
1966; MacMahon et al., 1971), to identify
potential responders to hormone therapy.
Renewed interest in the metabolism of
oestrogen in breast-cancer patients has
arisen because certain of the hydroxy-
metabolites can bind oestrogen receptor
without promoting target-cell growth
(Martucci & Fishman, 1976) and so might
act as protective agents against neoplastic
induction by biologically active oestro-
gens. For example, 2-hydroxyoestrone has
anti-oestrogenic action, and the ratio
2-hydroxyoestrone: oestradiol- 17/ is much
reduced in obese women, who constitute
one ofthe high-risk groups (Fishman et al.,
1975). Besides, the relationship between
dietary fat, oestrogen metabolism in
adipose tissue and breast-cancer incidence
is well recognized (Nimrod & Ryan, 1975).
In a comprehensive review, Dao (1979)
has argued that further analysis of abnor-
mal, particularly polar, oestrogen metabo-
lites in breast-cancer patients is urgently
needed. We therefore undertook a study of
excretion patterns of oestrogen metabo-
lites, including unusual metabolites, in
women with breast cancer, in relation to
their response to endocrine therapy.
MATERIALS AND METHODS
Patients. Sixty-three patients were
studied: they were of mean age 60-3 + 8-6
years and 3-15 (mean 10-2 +5.6) years post-
menopausal. All had previously undergone
mastectomy (simple or modified radical) but
had no adjuvant therapy, nor other endocrine
or cytotoxic therapy, during the 12 months
before entry into this study. All had ad-ENDOC'RINE THERAPY AND OESTROGEN METABOLISM 67
vanced disease. Metastatic disease was found
in 68% of cases, and 70% of this group had
distant metastases. Patients with metastases
which might directly influence steroid
metabolism (i.e. in liver, ovaries or adrenal
cortex) were excluded from this study.
On entry into the study each patient (a)
gave 3 24h urine specimens over a 15-day
period and (b) subsequently received additive
endocrine therapy (5 mg t.d. diethyl stilb-
estrol or hexoestrol). As a control, similar
urine samples were collected from 39 clinically
normal postmenopausal women (mean age
61-1 + 6-4; mean years postmenopausal 9-8 +
5.2). All patients attended the Cancer Centre
in Palermo for clinical assessment ofresponse
to treatment, which was made using UICC
guidelines by a member of the Cancer Centre
not involved in the study. For the purposes
of this study, patients were classified as
responders (complete plus partial response)
and non-responders (static plus progressive
disease).
Methods.-All materials were of Analar
grade. Oestrone (E1), oestradiol-17/ (E2) and
oestriol (E3) levels in urine samples were
determined by gas chromatography (and
additional mass spectrometry, where neces-
sary) as described previously (Castagnetta et
al., 1976; Paparopoli et al., 1977; see also
Kodama & Kodama, 1975). Briefly, a Carlo
Erba Fractovap GV equipped with a hydro-
gen-flame ionization detector was used with
2 different U-shaped glass columns, the first
being 150 x 0 4 cm and the second 225 x 0*4
cm and also partly coiled. The N2-inlet
pressure was about 2-0 kg/cm2, and flow rate
75 ml/min. To increase the definition of the
unusual, particularly polar, metabolites,
several different stationary phases were used.
Of these OV 17, OV 225-3% (Carlo Erba-
Milan) and OV 61-6% (a generous gift from
Professor L. Boniforti) yielded good results.
The unusual metabolites are reported as a
single concentration which represents total
detectable [16a-OH-oestrone+ 16-oxo-oest-
rone+2-OH & 4-OH-oestrone+2-OH & 4-
OH-17 oestradiol+ IA, 17a oestradiol+ 16-
oxo-17/ oestradiol+ 17a oestradiol+ 16-epi-
oestriol+ 16, 17-epioestriol + 17-epioestriol].
Statistical analy8i8.-The concentrations of
the different oestrogens detected have been
analysed by various parameters, and the
chosen mathematical expression is that which
shows the best fit to a normal distribution,
following Pearson's test (see Campbell, 1974).
Oestrogen excretions (ug/24 h) are expressed
as mean values + s.d.
Where necessary the values of the para-
meters chosen are also quoted as medians and
interquartile ranges. Statistical comparison
between values was always carried out by the
t test; for those parameters which showed a
wider dispersion, comparison was also made
using a non-parametric test (Wilcoxon's test).
To evaluate the efficiency of various para-
meters in detecting responders we have
applied sensitivity and specificity tests using
the formula:
P-FP
SensitivitY=p-FP+ FN
.. N-FN Specificity=N-FN+FP
where P represents positive, FP false-positive,
N negative and FN false-negative responders
on the basis of the selected parameter.
RESULTS
Sixty-three patients with advanced
breast cancer received endocrine therapy
as sole therapy. Ofthese, 24 (38%) showed
objective remission (complete or partial)
using UICC criteria. Each patient had
given 3 separate 24h urine samples before
the start of therapy. Concentrations of
steroid in each of the 3 samples were
averaged and recorded as ,tg/24 h. Three
similar urine samples were collected from
each of 39 clinically normal women
(Group C) and the steroid excretion pat-
terns similarly determined.
For analysis of the results the breast-
cancer patients were divided into respon-
ders (R) and non-responders (NR) to
endocrine therapy. For the 24 responders,
mean age was 62-4 + 4*5 and mean years
postmenopausal 12-4 + 3-8. For the 39
non-responders mean age was 58-6 + 7-4
and mean years postmenopausal 9.1 +
5-6. Then, in order to evaluate the statis-
tical significance, if any, between the 3
groups (C, R and NR), steroid excretion
was expressed as the logarithm of the
mean value for total oestrogens, unusual
metabolites and oestriol and as the square
root for classical oestrogens. The results
are shown in Table I.
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TABLE I. Urinary excretion patterns of steroids by breast-cancer patients and normal
women
Breast cancer
Significance of difference
Non- between groups
Function Controls Responders responders , A
measuired (C) (R) (NR) C-R C-NR R-NR
V/CE 3-833+0-436 3-804+ 1-114 4-793+ 1-551 NS P<0-001 P<0-005
Log TE 1-234+ 0-070 1-658 + 0-210 1-646 + 0-248 P < 0-001 P= 0 001 NS
Log UM 0-177 + 0-264 1-477 + 0-262 1-255 + 0-487 P < 0 001 P< 00001 NS
LogE3 0-971+0-100 0-713+0-379 1-114+0-385 P<0-05 P<0-05 P<0001
CE =classical oestrogens; TE = total oestrogens; UM=unusual metabolites; E3 =oestriol. Steroid excre-
tion was reported in ,ug/24 h, and mathematical functions taken as shown (mean+s.d.). For each function
the data in the control group fitted a normal distribution curve.
The data in Table I show that the most
significant difference between steroid ex-
cretion by normal women and those with
breast cancer is found by measuring
unusual metabolites. None of the 39 con-
trols secreted more than 10 Htg unusual
metabolites in 24 h. However, 55/63
breast-cancer patients exceeded this
figure. Similarly, a threshold value of
24 ,ug/24 h for total oestrogen excretion
was exceeded by 54/63 breast-cancer
patients, but by no controls. No good
discriminant between responders and non-
responders is seen, though only 4/24
responders secreted more than 20 ,ug/24 h
classical oestrogen, whereas 18 of the 39
non-responders did so.
In a further attempt to differentiate
between responders and non-responders
the oestriol ratio (E3R=E3/E1+E2) and
the ratio of classical oestrogens to unusual
metabolites (CE/UM) was calculated, as
was the product of the two ratios (CE/
UM x E3R). The results are shown in
Table II.
The data in Table II suggest that E3R
(as opposed to oestriol excretion alone)
gives some differentiation between respon-
ders and non-responders to endocrine
therapy. This confirms well established
data (Lemon et al., 1966; MacMahon
et al., 1971) but is still inadequate to
discriminate reliably between potential
responders and non-responders (Dao,
1979; Castagnetta et al., 1980a). The ratio
CE/UMis clearlyan excellent discriminant
between breast cancer patients and con-
trol women.
Patients who subsequently were classi-
fied as responders also showed a rise in
this ratio towards the control value during
therapy, whereas non-responders did not
(data not shown). This ratio might, there-
fore, prove very useful for monitoring
early response to therapy. The product of
the two ratios (CE/UM x E3R) is, perhaps,
the best function for discriminating be-
tween responders and non-responders.
We shall refer to it as the Pattern Index.
Applying the criteria of sensitivity and
TABLE II.-Statistical comparison of steroid excretion patterns in breast-cancer patients.
Median values and interquartile ranges
Normal
Steroid control group
ratio (C)
E3R 1-73
(1-56-1-86)
CE 12-50
UM (7-38-18-15)
CE 18-52
UM E3R (10-65-28-59)
Breast cancer
Non-
Responders responders
(R) (NR)
0-76 2-00
(0-36-1-57) (1-34-3-33)
0-46 0-92
(0-30-0-65) (0-51-2-49)
0-26 2-92
(0-17-0-94) (0-83-6-21)
'Wilcoxon's test (P values)
, K A~~~~
C-R C-NR R-NR
< 0-001 NS < 0-0001
< 0-0001 < 0-0001 < 0-001
< 0-0001 < 0-001 < 0-001
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specificity (as defined in the Statistical
Analysis section) to the parameters used in
Tables I and II, and taking the following
threshold values for each parameter, the
Classical Oestrogens (< 20 ,ug/24 h) show
good sensitivity in distinguishing respon-
ders (8333%) but mediocre specificity
(4877%) while E3R (< 1.0) shows very
good specificity (8466%) and only fair
sensitivity (58.3%); the only parameter
which appears valid in both respects is
the Pattern Index (< 2 0) which combines
excellent sensitivity (9.1 70) with reason-
able specificity (64.1 G,).
1)ISCUSSION
Previous work on urinary-oestrogen
excretion profiles in breast cancer has
failed to identify a reliable discriminant
between those who will respond to endo-
crine therapy and those who will not
(Bulbrook et al., 1971). E3R has been
shown to discriminate well between breast-
cancer patients and controls (Lemon et al.,
1966) and between different populations
of women with different incidences of
breast cancer (MacMahon et al., 1971).
However, the failure of E3R, and of other
indices of oestrogen excretion, reliably to
identify responders to endocrine therapy
has led Dao (1979) to propose the investi-
gation of excretion of unusual metabolites
of oestrogen by breast-cancer patients.
From the present studies it is clear that
excretion of unusual metabolites in sig-
nificant quantities ( >10 [g/24 h), though
never seen in clinically normal women, is
very common in breast-cancer patients
(55/63). However, excretion of unusual
metabolites cannot be taken as sole
indication of breast cancer, but rather as
an abnormality associated with endocrine
disorders, because they are also excreted
in endometrial and prostatic cancer (Cas-
tagnetta, 1979) and in some cases of
gynaecomastia andfibrocystic mastopathy
(Castagnetta et al., 1980b) and liver and
adrenocortical dysfunction. Nevertheless,
for patients with a known history of
breast cancer btut with none of these
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complications, the measurementofunusual
oestrogen-metabolite excretion might
prove most valuable, both predicting
response to therapy and subsequently
monitoring that response. The high level
of hydroxy metabolites excreted by
patients already suffering from breast
cancer does not support the theory that
they might act as protective agents
(Martucci & Fishman, 1976) but suggests
that they are products of metabolism
within the tumour cell. Since they are
excreted by both responders and non-
responders to endocrine therapy, this
metabolism is presumably not related to
the presence of receptor.
By combining excretion levels of classi-
cal oestrogens and of the unusual metabo-
lites with the oestriol ratio (CE/UM x E3R;
Table II) it becomes possible to distin-
guish most responders from non-respon-
ders. The range of this Pattern Index is
large, but the discrimination between
responders and non-responders, in terms
of both sensitivity (91-700) and specificity
(64.1%0) is good. Classical oestrogen excre-
tion is, of course, age-dependent, but the
mean ages of the 2 groups were reason-
ably comparable (62 for responders and
59 for non-responders).
One of the principal objectives of this
study was to establish whether the con-
centration of unusual metabolites ex-
creted was related to the oestrogen-
receptor (RE) status of the tumour. Since
the data in Table I suggest that similar
concentrations of unusual metabolites
are excreted by responders (R) and non-
responders (NR) to endocrine therapy and,
further, since it is known that functional
RE is normally associated with responding
tumours (Barnes et al., 1979; Leake et al.,
1]979), a direct correlation between
unusual-metabolite excretion and RE
concentration is unlikely. Nevertheless, a
close relationship between Pattern Index
and RE status could be predicted, and
appropriate studies are under way.
In conclusion, Pattern Index is a useful
index of potential response to endocrine
therapy. However, the principal current
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use for studies of excretion of oestrogen
metabolites, as described here, might be
in early detection ofthe disease, especially
in high-risk patients, and in monitoring
response to therapy, especially in patients
presenting with very advanced disease.
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